EcoDrugPlus

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSNBRG00000005467
Gene Symbol: DDR2
3 Cross references
190 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSNBRG00000023800
Gene Symbol: DDR2
3 Cross references
204 Possible Orthologues:

Disintegrin And Metalloproteinase Domain-Containing Protein 17-Like

Ensembl ID : ENSNBRG00000010379
Gene Symbol: LOC102778206
3 Cross references
208 Possible Orthologues:

Dopamine Receptor D1

Ensembl ID : ENSNBRG00000016428
Gene Symbol: DRD1
2 Cross references
188 Possible Orthologues:

Dopamine Receptor D1b

Ensembl ID : ENSNBRG00000005539
Gene Symbol: DRD1B
1 Cross references
198 Possible Orthologues:

Dopamine Receptor D2a

Ensembl ID : ENSNBRG00000007505
Gene Symbol: DRD2A
1 Cross references
208 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 1-Like

Ensembl ID : ENSNBRG00000000115
Gene Symbol: LOC102783872
3 Cross references
213 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 1-Like

Ensembl ID : ENSNBRG00000016125
Gene Symbol: LOC102795180
3 Cross references
213 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2-Like

Ensembl ID : ENSNBRG00000010940
Gene Symbol: LOC102797842
3 Cross references
212 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2-Like

Ensembl ID : ENSNBRG00000019941
Gene Symbol: LOC102792644
3 Cross references
200 Possible Orthologues:

Dual Specificity Protein Kinase Ttk-Like

Ensembl ID : ENSNBRG00000008089
Gene Symbol: LOC102795001
3 Cross references
204 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSNBRG00000023272
Gene Symbol: ENPP2
3 Cross references
226 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).